Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCaitlin R. RauschJJJeffrey L. JorgensenXWXuemei Wang

Discussion

Loading...

Member takes

Overview

Phase II trial shows blinatumomab improves MRD outcomes in B-cell ALL, indicating potential for low-level residual disease treatment.

Key Points

  • To evaluate the effectiveness of blinatumomab in inducing MRD-negativity in adults with B-cell ALL.
  • Prospective phase II study of blinatumomab in adults with measurable residual disease (MRD)
  • Eligible patients had B-cell ALL in morphologic remission with detectable MRD after prior therapy
  • Assessments included MRD response rates via next generation sequencing and clinical outcomes
  • 65% achieved MRD-negativity after 1 cycle, overall MRD response rate was 73%
  • Estimated 5-year overall survival rate was 60%, with improved outcomes for patients treated at lower MRD levels
  • 33% of responders proceeded to allogeneic stem cell transplantation, contributing to overall survival and relapse-free survival rates

Cite This Study

Rausch et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de76https://doi.org/10.1182/blood-2025-1575
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  2. 2Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  3. 3Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients2024
  4. 4The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease2024
  5. 5Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL2024 · 13 citations